UNSPSC 51162624: Dimemorfan

This classification denotes an antitussive agent and anticonvulsant agent with the molecular formula C18H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 623OAC38YU, chemically known as morphinan, 3,17-dimethyl-, (9alpha,13alpha,14alpha)- but more generally known as dimemorfan, which bears US NIH Compound Identifier 3037918. European Medicines Agency schedules Dimemorfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07158MIG.

UNSPSC 51162624 Dimemorfan, a Commodity code, nominally addresses a specific pharmaceutical active ingredient, but recent state and local solicitations under this code reflect broader pharmaceutical and drug-control product procurement rather than dimemorfan specifically. State and local governments are buying naloxone (an opioid antagonist), safe drug deactivation systems, and generic multi-source pharmaceuticals through this taxonomy. The issuing bodies span county health departments and state-administered cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the repeat buyers in recent opportunities.

Activity centers on Florida and Minnesota, with MMCAP's RFP extending to participating states including Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023 (note: the posted date of June 30, 2026 conflicts with the deadline year, suggesting a data inconsistency in the source). MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, with proposals due March 26, 2026 and contract effectiveness of July 1, 2026. The MMCAP procurement emphasizes cGMP and Drug Supply Chain Security Act compliance, pricing through authorized wholesalers, and performance penalties for reporting or onboarding failures. Neither solicitation identified explicit set-aside designations for disadvantaged enterprises.